<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00473967</url>
  </required_header>
  <id_info>
    <org_study_id>SVI-06-02</org_study_id>
    <nct_id>NCT00473967</nct_id>
  </id_info>
  <brief_title>Phase 1 Trial of Na-ASP-2 Hookworm Vaccine in Previously Infected Brazilian Adults</brief_title>
  <official_title>Double-blind, Randomized, Controlled Phase 1 Study of the Safety and Immunogenicity of Na-ASP-2 Hookworm Vaccine in Previously-Infected Brazilian Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert B. Sabin Vaccine Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oswaldo Cruz Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>George Washington University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert B. Sabin Vaccine Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Na-ASP-2 is a protein expressed during the larval stage of the N. americanus hookworm life&#xD;
      cycle. Vaccination with recombinant ASP-2 has protected dogs and hamsters from infection in&#xD;
      challenge studies. In a clinical study in hookworm-uninfected adults in the USA, Na-ASP-2&#xD;
      Hookworm Vaccine was safe and immunogenic. This study will evaluate its safety and&#xD;
      immunogenicity in individuals living in an area of endemic hookworm infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Double-blind, randomized, controlled Phase 1 clinical trial.&#xD;
&#xD;
        -  Study site: Americaninhas, Minas Gerais, Brazil.&#xD;
&#xD;
        -  Number of participants: 48 in three groups of 16, randomized to receive either Na-ASP-2&#xD;
           Hookworm Vaccine (n=36) or Butang® hepatitis B vaccine (n=12).&#xD;
&#xD;
        -  Study duration: 48 weeks; each participant will be followed for a total of 42 weeks.&#xD;
&#xD;
        -  Immunization schedule: Study days 0, 56 and 112.&#xD;
&#xD;
        -  Route: IM in the deltoid muscle.&#xD;
&#xD;
        -  Dose of Na-ASP-2: 10, 50 and 100 µg for the first, second and third dose cohort,&#xD;
           respectively.&#xD;
&#xD;
        -  Dose of Alhydrogel®: 800 µg for each dose of Na-ASP-2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Occurrence of unacceptable adverse events.&#xD;
  </why_stopped>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the frequency of vaccine-related adverse events, graded by severity, for each dose of the Na-ASP-2 Hookworm Vaccine</measure>
    <time_frame>For the duration of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the dose of Na-ASP-2 that generates the highest antibody response as determined by an indirect enzyme-linked immunosorbent assay (ELISA)</measure>
    <time_frame>2 weeks after the third injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess and compare the duration of antibody response to Na-ASP-2</measure>
    <time_frame>For the duration of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To perform exploratory studies of the cellular immune responses to the Na-ASP-2 antigen both before and after immunization</measure>
    <time_frame>For the duration of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Hookworm Infection</condition>
  <arm_group>
    <arm_group_label>10 mcg Na-ASP-2/Alhydrogel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Na-ASP-2 Hookworm Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Butang hepatitis B vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hepatitis B Vaccine - comparator vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Na-ASP-2 Hookworm Vaccine</intervention_name>
    <description>Injections of one of three different dose concentrations of the Na-ASP-2 vaccine (10, 50, or 100 mcg) vs. the hepatitis B vaccine, delivered at 0, 2, and 4 months by intramuscular injection.</description>
    <arm_group_label>10 mcg Na-ASP-2/Alhydrogel</arm_group_label>
    <arm_group_label>Butang hepatitis B vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females between 18 and 45 years, inclusive.&#xD;
&#xD;
          -  Known residents of the Municipality of Novo Oriente de Minas, Minas Gerais, Brazil.&#xD;
&#xD;
          -  Good general health as determined by means of the screening procedure.&#xD;
&#xD;
          -  Completed a 3-dose albendazole treatment for documented hookworm infection during the&#xD;
             previous 3 months.&#xD;
&#xD;
          -  Available for the duration of the trial (42 weeks).&#xD;
&#xD;
          -  Willingness to participate in the study as evidenced by signing the informed consent&#xD;
             document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy as determined by a positive urine β-hCG (if female).&#xD;
&#xD;
          -  Participant unwilling to use reliable contraception methods up until one month&#xD;
             following the third immunization (if female).&#xD;
&#xD;
          -  Currently lactating and breast-feeding (if female).&#xD;
&#xD;
          -  Inability to correctly answer all questions on the informed consent comprehension&#xD;
             questionnaire.&#xD;
&#xD;
          -  Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic,&#xD;
             rheumatologic, autoimmune, or renal disease by history, physical examination, and/or&#xD;
             laboratory studies.&#xD;
&#xD;
          -  Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator&#xD;
             affects the ability of the volunteer to understand and cooperate with the study&#xD;
             protocol.&#xD;
&#xD;
          -  Laboratory evidence of liver disease (alanine aminotransferase [ALT] greater than 64&#xD;
             U/l [females] or greater than 58 U/l [males]).&#xD;
&#xD;
          -  Laboratory evidence of renal disease (serum creatinine greater than 1.1 mg/dl&#xD;
             [females] or greater than 1.3 mg/dl [males], or more than trace protein or blood on&#xD;
             urine dipstick testing).&#xD;
&#xD;
          -  Laboratory evidence of hematologic disease (absolute leukocyte count &lt;3000/mm3 or&#xD;
             &gt;12.5 x 103/mm3; hemoglobin &lt;10.3 g/dl [females] or &lt;11.0 g/dl [males]; absolute&#xD;
             lymphocyte count &lt;900/mm3; or platelet count &lt;120,000/mm3).&#xD;
&#xD;
          -  Other condition that in the opinion of the investigator would jeopardize the safety or&#xD;
             rights of a volunteer participating in the trial or would render the subject unable to&#xD;
             comply with the protocol.&#xD;
&#xD;
          -  Participation in another investigational vaccine or drug trial within 30 days of&#xD;
             starting this study.&#xD;
&#xD;
          -  Volunteer has had medical, occupational, or family problems as a result of alcohol or&#xD;
             illicit drug use during the past 12 months.&#xD;
&#xD;
          -  History of a severe allergic reaction or anaphylaxis.&#xD;
&#xD;
          -  Severe asthma as defined by the need for regular use of inhalers or emergency clinic&#xD;
             visit or hospitalization within the last 6 months.&#xD;
&#xD;
          -  Positive ELISA for HCV.&#xD;
&#xD;
          -  Positive ELISA for HBsAg.&#xD;
&#xD;
          -  Known immunodeficiency syndrome.&#xD;
&#xD;
          -  Use of corticosteroids (excluding topical or nasal) or immunosuppressive drugs within&#xD;
             30 days of starting this study.&#xD;
&#xD;
          -  Receipt of a live vaccine within past 4 weeks or a killed vaccine within past 2 weeks&#xD;
             prior to entry into the study.&#xD;
&#xD;
          -  History of a surgical splenectomy.&#xD;
&#xD;
          -  Receipt of blood products within the past 6 months.&#xD;
&#xD;
          -  Previous receipt of a primary series of any hepatitis B vaccine.&#xD;
&#xD;
          -  History of allergy to yeast.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J Diemert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert B. Sabin Vaccine Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro de Pesquisas Rene Rachou</name>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.sabin.org</url>
    <description>Sponsor's Web page</description>
  </link>
  <link>
    <url>http://www.cpqrr.fiocruz.br</url>
    <description>Trial site website</description>
  </link>
  <results_reference>
    <citation>Diemert DJ, Pinto AG, Freire J, Jariwala A, Santiago H, Hamilton RG, Periago MV, Loukas A, Tribolet L, Mulvenna J, Correa-Oliveira R, Hotez PJ, Bethony JM. Generalized urticaria induced by the Na-ASP-2 hookworm vaccine: implications for the development of vaccines against helminths. J Allergy Clin Immunol. 2012 Jul;130(1):169-76.e6. doi: 10.1016/j.jaci.2012.04.027. Epub 2012 May 26.</citation>
    <PMID>22633322</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>May 14, 2007</study_first_submitted>
  <study_first_submitted_qc>May 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2007</study_first_posted>
  <last_update_submitted>July 6, 2012</last_update_submitted>
  <last_update_submitted_qc>July 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>Hookworm</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Na-ASP-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hookworm Infections</mesh_term>
    <mesh_term>Ancylostomiasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

